BioRestorative Therapies - BRTX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $15.00
  • Forecasted Upside: 757.14%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.75
▼ -0.07 (-3.85%)

This chart shows the closing price for BRTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BioRestorative Therapies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BRTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BRTX

Analyst Price Target is $15.00
▲ +757.14% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for BioRestorative Therapies in the last 3 months. The average price target is $15.00, with a high forecast of $15.00 and a low forecast of $15.00. The average price target represents a 757.14% upside from the last price of $1.75.

This chart shows the closing price for BRTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in BioRestorative Therapies. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/22/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/22/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/21/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/19/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/17/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/16/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/15/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/15/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/14/2023Roth MkmReiterated RatingBuy ➝ Buy$15.00
12/7/2022Roth CapitalInitiated CoverageBuy$15.00
9/28/2022Maxim GroupInitiated CoverageBuy
12/1/2021Roth CapitalInitiated CoverageBuy$37.00
(Data available from 7/15/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/18/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/17/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/16/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/17/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/16/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/16/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/15/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/15/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
BioRestorative Therapies logo
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.
Read More

Today's Range

Now: $1.75
Low: $1.72
High: $1.85

50 Day Range

MA: $1.59
Low: $1.16
High: $2.22

52 Week Range

Now: $1.75
Low: $1.03
High: $3.67

Volume

63,300 shs

Average Volume

1,258,829 shs

Market Capitalization

$11.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

63.43

Frequently Asked Questions

What sell-side analysts currently cover shares of BioRestorative Therapies?

The following Wall Street sell-side analysts have issued research reports on BioRestorative Therapies in the last year: Roth Mkm.
View the latest analyst ratings for BRTX.

What is the current price target for BioRestorative Therapies?

1 Wall Street analysts have set twelve-month price targets for BioRestorative Therapies in the last year. Their average twelve-month price target is $15.00, suggesting a possible upside of 757.1%. Roth Mkm has the highest price target set, predicting BRTX will reach $15.00 in the next twelve months. Roth Mkm has the lowest price target set, forecasting a price of $15.00 for BioRestorative Therapies in the next year.
View the latest price targets for BRTX.

What is the current consensus analyst rating for BioRestorative Therapies?

BioRestorative Therapies currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BRTX will outperform the market and that investors should add to their positions of BioRestorative Therapies.
View the latest ratings for BRTX.

What other companies compete with BioRestorative Therapies?

Other companies that are similar to BioRestorative Therapies include LianBio, BiomX, iBio, PHAXIAM Therapeutics and NovaBay Pharmaceuticals. Learn More about companies similar to BioRestorative Therapies.

How do I contact BioRestorative Therapies' investor relations team?

BioRestorative Therapies' physical mailing address is 40 MARCUS DRIVE, MELVILLE NY, 11747. The company's listed phone number is (631) 760-8100 and its investor relations email address is [email protected]. The official website for BioRestorative Therapies is www.biorestorative.com. Learn More about contacing BioRestorative Therapies investor relations.